KARAASLAN, Z. Et Al. 2022. CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients. EUROPEAN NEUROLOGY , vol.85, no.1 , 69-71.

KARAASLAN, Z., KÜRTÜNCÜ, M., Akcay, H. I., GÜNDÜZ, T., Altunrende, B., Turkoglu, R., ... ERAKSOY, M.(2022). CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients. EUROPEAN NEUROLOGY , vol.85, no.1, 69-71.

KARAASLAN, Zerrin Et Al. "CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients," EUROPEAN NEUROLOGY , vol.85, no.1, 69-71, 2022

KARAASLAN, Zerrin Et Al. "CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients." EUROPEAN NEUROLOGY , vol.85, no.1, pp.69-71, 2022

KARAASLAN, Z. Et Al. (2022) . "CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients." EUROPEAN NEUROLOGY , vol.85, no.1, pp.69-71.

@article{article, author={Zerrin KARAASLAN Et Al. }, title={CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients}, journal={EUROPEAN NEUROLOGY}, year=2022, pages={69-71} }